Uzedy administered once every 2 months is not recommended for the maintenance treatment of bipolar I disorder. The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release ...
A large study shows risperidone raises stroke risk in patients with dementia, even those without cardiovascular disease — ...
A major U.K. study of more than 165,000 dementia patients has found that risperidone raises stroke risk without exception, ...
The FDA has approved risperidone once-monthly, extended-release injectable suspension for maintenance treatment of bipolar I ...
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) ...
GlobalData on MSN
FDA approves Teva and Medincell’s bipolar I disorder treatment
The once-a-month extended-release injectable suspension incorporates Medincell's copolymer technology. Credit: ...
A major U.K. study of more than 165,000 dementia patients has found that risperidone raises stroke risk without exception, ...
This is a developing news story. Please check back soon for updates. The FDA approved extended-release Uzedy for the ...
A UK study of more than 165,000 dementia patients has found that an anti-psychotic medication called Risperidone raises stroke risk without exception, challenging safety assumptions by leaving no ...
FDA approves UZEDY ® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback